// App-Quantinova.ai

e12033 : A trail of neoadjuvant recombinant human endostatin in combination with docetaxel, epirubicin, and cyclophosphamide in breast cancer patients.

Researchers

Presenter

  • Yunjiang Liu

Principal Investigators

  • Miao Cao

  • Yueping Liu

  • Xiangmei Zhang

Medical Centers

  • Breast canter, Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Microvessel density

  • Nuclear receptor subfamily 4 group A member 3

  • Vascular endothelial growth factor A

Drug/Treatment

  • Recombinant human endostatin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • M2ES

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved